Commentary On Sofosbuvir + Ribavirin And Other Top Liver Abstracts From EASL and DDW 2013

Gastroenterology & Endoscopy News
ISSUE: AUGUST 2013 | VOLUME: 64:8

Experts' Picks: Top Liver Abstracts 
From EASL and DDW 2013
 Aug 13 2013

In the August edition of Gastroenterology & Endoscopy News three hepatologists offer commentary on the top liver abstracts presented at The International Liver Congress 2013/ European Association for the Study of the Liver (EASL) and the 2013 Digestive Disease Week (DDW) meeting.

The following abstracts are included:

Patrick Basu, MD
Assistant Clinical Professor
Department of Digestive and Liver Diseases
Columbia University College of Physicians and Surgeons
New York, New York
Clinical Professor
Hofstra North Shore-LIJ School of Medicine
Hofstra University
Hempstead, New York

Sofosbuvir + Peginterferon + Ribavirin for 12 Weeks Achieves 90% SVR12 in Genotype 1, 4, 5, or 6 HCV Infected Patients: The NEUTRINO Study (Lawitz E et al. EASL Abstract 1411)

All Oral Therapy With Sofosbuvir + Ribavirin for 12 or 16 Weeks in Treatment Experienced GT2/3 HCV-Infected Patients: Results of the Phase 3 FUSION Trial (Nelson DR et al. EASL Abstract 6)

Telaprevir With Adjusted Dose of Ribavirin in Naive CHC-G1: Efficacy and Treatment in CHC in Hemodialysis Population. Target C Trial—A Placebo Randomized Control Clinical Trial (Basu P et al. DDW Abstract 517)


Jordan Feld, MD, MPH
Assistant Professor of Medicine
University of Toronto
Toronto, Canada
Staff Hepatologist
Division of Gastroenterology
Department of Medicine
Toronto Western Hospital
Toronto, Canada

All-Oral Sofosbuvir-Based 12-Week Regimens for the Treatment of Chronic HCV Infection: The ELECTRON Study (Gane EJ et al. EASL Abstract 14)

SVR12 Rates and Safety of Triple Therapy Including Telaprevir or Boceprevir in 221 Cirrhotic Non Responders Treated in the French Early Access Program (ANRS CO20-CUPIC) (Fontaine H et al. EASL Abstract 60)




Jacqueline O’Leary, MD, MPH
Medical Director
Inpatient Liver and Transplant Unit
Baylor University Medical Center
Dallas, Texas



Safety and Efficacy of Interferon-Free Regimens of ABT-450/R, ABT-267, ABT-333 ± Ribavirin in Patients With Chronic HCV GT1 Infection: Results From The AVIATOR Study (Kowdley KV et al. EASL Abstract 3)

Sustained Virologic Response With Daclatasvir Plus Sofosbuvir ± Ribavirin (RBV) in Chronic HCV Genotype (GT) 1–Infected Patients Who Previously Failed Telaprevir (TVR) or Boceprevir (BOC) (Sulkowski MS et al. EASL Abstract 1417)

Natural History of Inflammatory Bowel Disease After Liver Transplantation for Primary Sclerosing Cholangitis (Singh S et al. DDW Abstract 40)

 View All Top Picks and Comments here .....

Free Registration May Be Required